Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reduxine is a combination weight-loss medication primarily marketed in Russia and CIS countries. It consists of sibutramine, a serotonin-norepinephrine reuptake inhibitor (SNRI), and microcrystalline cellulose. Sibutramine acts centrally in the hypothalamus to inhibit the reuptake of serotonin, norepinephrine, and to a lesser extent, dopamine, which leads to increased satiety and enhanced thermogenesis. The microcrystalline cellulose component serves as an enteric adsorbent and a bulking agent to further promote a feeling of fullness. While sibutramine was withdrawn from major international markets, including the United States and the European Union, in 2010 due to concerns over increased cardiovascular risks (such as stroke and myocardial infarction) identified in the SCOUT trial, Reduxine remains a widely prescribed pharmaceutical treatment for obesity and metabolic syndrome in specific jurisdictions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sibutramine + microcrystalline cellulose.